




Page 1 of 1
(page number not for citation purposes)
Cancer Cell International
Open AccessOral presentation
Adoptive T cell therapy using antigen-specific CD8+ T cells for the 
treatment of patients with metastatic melanoma: a phase I clinical 
study
N Meidenbauer, S Vogl, M Laumer, J Heymann, R Andreesen and 
A Mackensen*
Address: Department of Hematology/Oncology, University of Regensburg, D-93042 Regensburg, Germany
Email: A Mackensen* - andreas.mackensen@klinik.uni-regensburg.de
* Corresponding author    
The adoptive transfer of in vitro induced and expanded
tumor antigen-specific cytotoxic T lymphocytes (CTL)
provides a promising approach to the immunotherpy of
cancer. We have previously shown that Melan-A-specific
CTL can be generated from HLA-A2.1+ melanoma patients
by 4 rounds of in vitro stimulation of purified CD8+ T cells
with autologous dendritic cells pulsed with a mutated
HLA-A2 binding Melan-A (ELAGIGILTV) peptide. Based
on these results we have initiated a pilot study of adoptive
T cell therapy in advanced melanoma patients demon-
strating that in vitro generated Melan-A specific CTL sur-
vive intact in vivo for several weeks and localize
preferentially to tumor (Meidenbauer et al., J Immunol
2003, 170:2161, 2003). Here we report on the clinical
results of a phase I study of 12 HLA-A2+ melanoma
patients that received at least three i.v. infusions of Melan-
A-specific CTL i.v. at 2-week intervals. Each T cell infusion
was accompanied by a 6-day course of s.c. IL-2 (3 × 106 IU
daily). A total of 51 T-cell infusions were administered,
averaging 1.48 × 108 Melan-A multimer+ T cells per infu-
sion, with a range from 0.11–6.58 × 108 Melan-A-specific
T cells per infusion. Clinical side effects were mild and
consisted of chills and low-grade fever (WHO grade I-II)
in 8 out of 12 patients that typically occurred within 6 to
8 h post infusion. Hematological effects, observed after T
cell transfer, consisted of an increase in eosinophils up to
30% in 7 out of 12 patients, peaking 24 h post transfer.
Clinical and immunological responses consisted of anti-
tumor responses in 3 out of 12 patients (2 PR, 1 mixed
response), an elevated frequency of circulating Melan-A
multimer+ T cells up to 2% of total CD8+ T cells up to 14
days post transfer, suggesting long-term survival and/or
proliferation of transferred CTL, and a complete loss of
Melan-A expression in lymph node metastases of 2
patients after T cell transfer. Our data indicate that the
adoptive transfer of antigen-specific T cells in melanoma
patients is capable of inducing clinical and systemic
tumor-specific immune responses without provoking
major side effects.
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